User profiles for A. Royuela

Ana Royuela

Biostatistics Unit; Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA …
Verified email at idiphim.org
Cited by 6583

[HTML][HTML] Prescripción potencialmente inapropiada en mayores de 65 años en un centro de salud de atención primaria

NP López, YFV Villán, MIG Menéndez, A Royuela - Atención primaria, 2014 - Elsevier
Objetivo Identificar las prescripciones potencialmente inapropiadas (PPI) y omisiones de
prescripción (OP) mediante los criterios STOPP/START y factores asociados en pacientes ≥ …

Steroid avoidance or withdrawal for kidney transplant recipients

MC Haller, A Royuela, EV Nagler… - Cochrane Database …, 2016 - cochranelibrary.com
Background Steroid‐sparing strategies have been attempted in recent decades to avoid
morbidity from long‐term steroid intake among kidney transplant recipients. Previous systematic …

Steroid avoidance or withdrawal for kidney transplant recipients

…, J Zamora, C Galeano, A Royuela… - Cochrane Database …, 2009 - cochranelibrary.com
Background Steroid‐sparing strategies have been attempted during the last two decades in
order to avoid morbidity in kidney transplant recipients. Previous systematic reviews of …

Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients

J Pascual, A Royuela, AM Fernández… - Transplant Infectious …, 2016 - Wiley Online Library
Appropriate post‐transplant immunosuppressive regimens that avoid acute rejection, while
reducing risk of viral reactivation, have been sought, but remain a chimera. Recent evidence …

[PDF][PDF] Disfunción sexual femenina: estudio de prevalencia en mujeres premenopáusicas

SP Sánchez, TP Medina, A Royuela - Progresos de obstetricia y …, 2017 - researchgate.net
Aim: To determine the prevalence of female sexual dysfunction among premenopausal women.
Material and methods: Longitudinal study. 120 women were selected in a clinic in Madrid…

[HTML][HTML] Bronchopulmonary infection–colonization patterns in Spanish cystic fibrosis patients: Results from a national multicenter study

J de Dios Caballero, R Del Campo, A Royuela… - Journal of Cystic …, 2016 - Elsevier
Background Clinical and demographical knowledge on Spanish cystic fibrosis (CF) patients
is incomplete as no national registry exists. CF-microbiology has not been studied at …

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

…, IB Aranda, S Viteri, E Pereira, A Royuela… - The Lancet …, 2020 - thelancet.com
Background Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally
advanced stage disease. We aimed to assess the antitumour activity and safety of neoadjuvant …

Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non–small-cell lung cancer (NADIM phase II trial)

…, S Viteri, E Pereira, A Royuela… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in
resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials.gov identifier…

[HTML][HTML] Minimum detectable and minimal clinically important changes for pain in patients with nonspecific neck pain

FM Kovacs, V Abraira, A Royuela, J Corcoll… - BMC musculoskeletal …, 2008 - Springer
Background The minimal detectable change (MDC) and the minimal clinically important
changes (MCIC) have been explored for nonspecific low back pain patients and are similar …

Minimal clinically important change for pain intensity and disability in patients with nonspecific low back pain

FM Kovacs, V Abraira, A Royuela, J Corcoll, L Alegre… - Spine, 2007 - journals.lww.com
Study Design. Cohort study. Objective. To estimate the minimal clinically important change (MCIC)
on the pain intensity numerical rating scale (PI-NRS) and the Roland Morris Disability …